Download PDF
Digestive Disease Interventions
DOI: 10.1055/s-0045-1808265
Review Article

New Insights in Diagnosing and Risk-Stratifying Pancreatic Cystic Neoplasms and IPMN

Tommaso Pollini 
1   Division of Surgical Oncology, Department of Surgery, University of California San Francisco, San Francisco, California
,
Ajay V. Maker
1   Division of Surgical Oncology, Department of Surgery, University of California San Francisco, San Francisco, California
› Author Affiliations Funding Acknowledgement to the Shorenstein Family Foundation, Baker and Simpson Family Research Fund, Illinois Ventures, and Inner Child Foundation.
› Further Information
Also available at
    Permissions and Reprints

Abstract

Pancreatic cystic neoplasms (PCN) comprise a diverse group of lesions with variable malignant potential, requiring accurate diagnosis and risk stratification for appropriate management. Distinguishing mucinous cysts, including intraductal papillary mucinous neoplasms (IPMN) and mucinous cystic neoplasms (MCN), from benign nonmucinous lesions such as serous cystadenomas (SCA) is essential due to their risk of progression to invasive carcinoma. Importantly, IPMN and MCN represent the only radiologically detectable precursors to pancreatic cancer, contributing to 15% of cases. Traditional diagnostic approaches utilize imaging modalities like computed tomography, magnetic resonance imaging, and endoscopic ultrasound (EUS), often supported by cyst fluid analysis through fine-needle aspiration. However, these techniques exhibit limited sensitivity and specificity in identifying malignant transformation. Emerging molecular diagnostics, including analysis of carcinoembryonic antigen, glucose, IL1β, PGE2, and DNA sequencing for mutations such as KRAS and GNAS, show promise in differentiating mucinous cysts and identifying advanced dysplasia. Despite this, clinical integration remains limited. Future efforts focus on noninvasive methods, including plasma-based liquid biopsies, to complement cyst fluid analysis. A comprehensive biomarker panel integrating serum and cyst fluid markers holds the potential to improve early detection, reduce overtreatment, and optimize surgical management of high-risk PCN.

Keywords

IPMN - pancreas - pancreatic cystic neoplasms - intraductal papillary mucinous neoplasms


Publication History

Received: 24 January 2025

Accepted: 08 April 2025

Article published online:
19 May 2025

© 2025. Thieme. All rights reserved.

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA

 

  • References

  • 1 Gonda TA, Cahen DL, Farrell JJ. Pancreatic cysts. N Engl J Med 2024; 391 (09) 832-843
    PubMedSearch in Google Scholar
  • 2 Khoury RE, Kabir C, Maker VK, Banulescu M, Wasserman M, Maker AV. What is the incidence of malignancy in resected intraductal papillary mucinous neoplasms? An analysis of over 100 US institutions in a single year. Ann Surg Oncol 2018; 25 (06) 1746-1751
    PubMedSearch in Google Scholar
  • 3 Maker AV, Katabi N, Gonen M. et al. Pancreatic cyst fluid and serum mucin levels predict dysplasia in intraductal papillary mucinous neoplasms of the pancreas. Ann Surg Oncol 2011; 18 (01) 199-206
    PubMedSearch in Google Scholar
  • 4 Pollini T, Todeschini L, Maker AV. Pancreas cyst diagnosis and advances in cyst fluid analysis. Surg Clin North Am 2024; 104 (05) 965-974
    PubMedSearch in Google Scholar
  • 5 Maker AV. ASO author reflections: improving identification of intraductal papillary mucinous neoplasm patients at risk-current status and the role of IPMN molecular biomarkers. Ann Surg Oncol 2018; 25 (Suppl. 03) 818-819
    PubMedSearch in Google Scholar
  • 6 Tulla KA, Maker AV. Can we better predict the biologic behavior of incidental IPMN? A comprehensive analysis of molecular diagnostics and biomarkers in intraductal papillary mucinous neoplasms of the pancreas. Langenbecks Arch Surg 2018; 403 (02) 151-194
    PubMedSearch in Google Scholar
  • 7 Maker AV, Carrara S, Jamieson NB. et al. Cyst fluid biomarkers for intraductal papillary mucinous neoplasms of the pancreas: a critical review from the international expert meeting on pancreatic branch-duct-intraductal papillary mucinous neoplasms. J Am Coll Surg 2015; 220 (02) 243-253
    PubMedSearch in Google Scholar
  • 8 Pollini T, Wong P, Maker AV. The landmark series: intraductal papillary mucinous neoplasms of the pancreas - from prevalence to early cancer detection. Ann Surg Oncol 2023; 30 (03) 1453-1462
    PubMedSearch in Google Scholar
  • 9 Ohtsuka T, Fernandez-Del Castillo C, Furukawa T. et al. International evidence-based Kyoto guidelines for the management of intraductal papillary mucinous neoplasm of the pancreas. Pancreatology 2024; 24 (02) 255-270
    CrossrefPubMedSearch in Google Scholar
  • 10 European Study Group on Cystic Tumours of the Pancreas. European evidence-based guidelines on pancreatic cystic neoplasms. Gut 2018; 67 (05) 789-804
    CrossrefPubMedSearch in Google Scholar
  • 11 Marchegiani G, Pollini T, Andrianello S. et al. Progression vs cyst stability of branch-duct intraductal papillary mucinous neoplasms after observation and surgery. JAMA Surg 2021; 156 (07) 654-661
    CrossrefPubMedSearch in Google Scholar
  • 12 Vilas-Boas F, Ribeiro T, Macedo G. et al. Endoscopic ultrasound-guided through-the-needle biopsy: a narrative review of the technique and its emerging role in pancreatic cyst diagnosis. Diagnostics (Basel) 2024; 14 (15) 1587
    PubMedSearch in Google Scholar
  • 13 Tanaka M, Fernández-Del Castillo C, Kamisawa T. et al. Revisions of international consensus Fukuoka guidelines for the management of IPMN of the pancreas. Pancreatology 2017; 17 (05) 738-753
    CrossrefPubMedSearch in Google Scholar
  • 14 Tanaka M, Fernández-del Castillo C, Adsay V. et al; International Association of Pancreatology. International consensus guidelines 2012 for the management of IPMN and MCN of the pancreas. Pancreatology 2012; 12 (03) 183-197
    CrossrefPubMedSearch in Google Scholar
  • 15 Tanaka M, Chari S, Adsay V. et al; International Association of Pancreatology. International consensus guidelines for management of intraductal papillary mucinous neoplasms and mucinous cystic neoplasms of the pancreas. Pancreatology 2006; 6 (1-2): 17-32
    CrossrefPubMedSearch in Google Scholar
  • 16 Pflüger MJ, Jamouss KT, Afghani E. et al. Predictive ability of pancreatic cyst fluid biomarkers: a systematic review and meta-analysis. Pancreatology 2023; 23 (07) 868-877
    CrossrefPubMedSearch in Google Scholar
  • 17 Tacelli M, Celsa C, Magro B. et al. Diagnostic performance of endoscopic ultrasound through-the-needle microforceps biopsy of pancreatic cystic lesions: systematic review with meta-analysis. Dig Endosc 2020; 32 (07) 1018-1030
    CrossrefPubMedSearch in Google Scholar
  • 18 Maker AV, Lee LS, Raut CP, Clancy TE, Swanson RS. Cytology from pancreatic cysts has marginal utility in surgical decision-making. Ann Surg Oncol 2008; 15 (11) 3187-3192
    PubMedSearch in Google Scholar
  • 19 Magahis PT, Chhoda A, Berzin TM. et al. Risk of pancreatitis after endoscopic ultrasound-guided fine-needle aspiration of pancreatic cystic lesions: a systematic review and meta-analysis. Am J Gastroenterol 2024; 119 (11) 2174-2186
    PubMedSearch in Google Scholar
  • 20 Kwan MC, Pitman MB, Fernandez-Del Castillo C, Zhang ML. Revisiting the performance of cyst fluid carcinoembryonic antigen as a diagnostic marker for pancreatic mucinous cysts: a comprehensive 20-year institutional review. Gut 2024; 73 (04) 629-638
    PubMedSearch in Google Scholar
  • 21 Mohan BP, Madhu D, Khan SR. et al. Intracystic glucose levels in differentiating mucinous from nonmucinous pancreatic cysts: a systematic review and meta-analysis. J Clin Gastroenterol 2022; 56 (02) e131-e136
    CrossrefPubMedSearch in Google Scholar
  • 22 Rossi G, Petrone MC, Tacelli M. et al. Glucose and lactate levels are lower in EUS-aspirated cyst fluid of mucinous vs non-mucinous pancreatic cystic lesions. Dig Liver Dis 2024; 56 (05) 836-840
    CrossrefPubMedSearch in Google Scholar
  • 23 Williet N, Caillol F, Karsenti D. et al. The level of glucose in pancreatic cyst fluid is more accurate than carcinoembryonic antigen to identify mucinous tumors: a French multicenter study. Endosc Ultrasound 2023; 12 (04) 377-381
    PubMedSearch in Google Scholar
  • 24 Gorris M, Dijk F, Farina A. et al. Validation of combined carcinoembryonic antigen and glucose testing in pancreatic cyst fluid to differentiate mucinous from non-mucinous cysts. Surg Endosc 2023; 37 (05) 3739-3746
    CrossrefPubMedSearch in Google Scholar
  • 25 Smith ZL, Satyavada S, Simons-Linares R. et al. Intracystic glucose and carcinoembryonic antigen in differentiating histologically confirmed pancreatic mucinous neoplastic cysts. Am J Gastroenterol 2022; 117 (03) 478-485
    PubMedSearch in Google Scholar
  • 26 Lee JH, Kim Y, Choi JW, Kim YS. KRAS, GNAS, and RNF43 mutations in intraductal papillary mucinous neoplasm of the pancreas: a meta-analysis. Springerplus 2016; 5 (01) 1172
    PubMedSearch in Google Scholar
  • 27 Berger AW, Schwerdel D, Costa IG. et al. Detection of hot-spot mutations in circulating cell-free DNA from patients with intraductal papillary mucinous neoplasms of the pancreas. Gastroenterology 2016; 151 (02) 267-270
    PubMedSearch in Google Scholar
  • 28 Okada T, Mizukami Y, Ono Y. et al. Digital PCR-based plasma cell-free DNA mutation analysis for early-stage pancreatic tumor diagnosis and surveillance. J Gastroenterol 2020; 55 (12) 1183-1193
    PubMedSearch in Google Scholar
  • 29 Park MA, Zaw T, Yoder SJ. et al. A pilot study to evaluate tissue- and plasma-based DNA driver mutations in a cohort of patients with pancreatic intraductal papillary mucinous neoplasms. G3 (Bethesda) 2023; 13 (02) jkac314
    PubMedSearch in Google Scholar
  • 30 Hata T, Mizuma M, Motoi F. et al. GNAS mutation detection in circulating cell-free DNA is a specific predictor for intraductal papillary mucinous neoplasms of the pancreas, especially for intestinal subtype. Sci Rep 2020; 10 (01) 17761
    PubMedSearch in Google Scholar
  • 31 Nitschke C, Tölle M, Walter P. et al. KRAS and GNAS mutations in cell-free DNA and in circulating epithelial cells in patients with intraductal papillary mucinous neoplasms-an observational pilot study. Mol Oncol 2024;
    CrossrefPubMedSearch in Google Scholar
  • 32 Paniccia A, Polanco PM, Boone BA. et al. Prospective, multi-institutional, real-time next-generation sequencing of pancreatic cyst fluid reveals diverse genomic alterations that improve the clinical management of pancreatic cysts. Gastroenterology 2023; 164 (01) 117-133.e7
    CrossrefPubMedSearch in Google Scholar
  • 33 Iyer MK, Shi C, Eckhoff AM, Fletcher A, Nussbaum DP, Allen PJ. Digital spatial profiling of intraductal papillary mucinous neoplasms: toward a molecular framework for risk stratification. Sci Adv 2023; 9 (11) eade4582
    PubMedSearch in Google Scholar
  • 34 Iyer MK, Fletcher A, Okoye JO. et al. Spatial transcriptomics of intraductal papillary mucinous neoplasms reveals divergent indolent and malignant states. Clin Cancer Res 2025;
    CrossrefPubMedSearch in Google Scholar
  • 35 Moffitt RA, Marayati R, Flate EL. et al. Virtual microdissection identifies distinct tumor- and stroma-specific subtypes of pancreatic ductal adenocarcinoma. Nat Genet 2015; 47 (10) 1168-1178
    CrossrefPubMedSearch in Google Scholar
  • 36 Collisson EA, Sadanandam A, Olson P. et al. Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy. Nat Med 2011; 17 (04) 500-503
    CrossrefPubMedSearch in Google Scholar
  • 37 Agostini A, Piro G, Inzani F. et al. Identification of spatially-resolved markers of malignant transformation in intraductal papillary mucinous neoplasms. Nat Commun 2024; 15 (01) 2764
    PubMedSearch in Google Scholar
  • 38 Pollini T, Adsay V, Capurso G. et al. The tumour immune microenvironment and microbiome of pancreatic intraductal papillary mucinous neoplasms. Lancet Gastroenterol Hepatol 2022; 7 (12) 1141-1150
    PubMedSearch in Google Scholar
  • 39 Maker AV, Katabi N, Qin LX. et al. Cyst fluid interleukin-1beta (IL1beta) levels predict the risk of carcinoma in intraductal papillary mucinous neoplasms of the pancreas. Clin Cancer Res 2011; 17 (06) 1502-1508
    PubMedSearch in Google Scholar
  • 40 Maker AV, Hu V, Kadkol SS. et al. Cyst fluid biosignature to predict intraductal papillary mucinous neoplasms of the pancreas with high malignant potential. J Am Coll Surg 2019; 228 (05) 721-729
    PubMedSearch in Google Scholar
  • 41 Schmidt CM, Yip-Schneider MT, Ralstin MC. et al. PGE(2) in pancreatic cyst fluid helps differentiate IPMN from MCN and predict IPMN dysplasia. J Gastrointest Surg 2008; 12 (02) 243-249
    PubMedSearch in Google Scholar
  • 42 Simpson RE, Yip-Schneider MT, Flick KF, Wu H, Colgate CL, Schmidt CM. Pancreatic fluid interleukin-1β complements prostaglandin E2 and serum carbohydrate antigen 19-9 in prediction of intraductal papillary mucinous neoplasm dysplasia. Pancreas 2019; 48 (08) 1026-1031
    PubMedSearch in Google Scholar
  • 43 Arima K, Okabe H, Hashimoto D. et al. The neutrophil-to-lymphocyte ratio predicts malignant potential in intraductal papillary mucinous neoplasms. J Gastrointest Surg 2015; 19 (12) 2171-2177
    PubMedSearch in Google Scholar
  • 44 Gemenetzis G, Bagante F, Griffin JF. et al. Neutrophil-to-lymphocyte ratio is a predictive marker for invasive malignancy in intraductal papillary mucinous neoplasms of the pancreas. Ann Surg 2017; 266 (02) 339-345
    PubMedSearch in Google Scholar
  • 45 McIntyre CA, Pulvirenti A, Lawrence SA. et al. Neutrophil-to-lymphocyte ratio as a predictor of invasive carcinoma in patients with intraductal papillary mucinous neoplasms of the pancreas. Pancreas 2019; 48 (06) 832-836
    PubMedSearch in Google Scholar
  • 46 Sugimachi K, Mano Y, Matsumoto Y. et al. Neutrophil-to-lymphocyte ratio as a predictor of malignancy of intraductal papillary mucinous neoplasms. Anticancer Res 2021; 41 (03) 1663-1669
    PubMedSearch in Google Scholar
  • 47 Hernandez S, Parra ER, Uraoka N. et al. Diminished immune surveillance during histologic progression of intraductal papillary mucinous neoplasms offers a therapeutic opportunity for cancer interception. Clin Cancer Res 2022; 28 (09) 1938-1947
    PubMedSearch in Google Scholar
  • 48 Bernard V, Semaan A, Huang J. et al. Single-cell transcriptomics of pancreatic cancer precursors demonstrates epithelial and microenvironmental heterogeneity as an early event in neoplastic progression. Clin Cancer Res 2019; 25 (07) 2194-2205
    PubMedSearch in Google Scholar
  • 49 Eckhoff AM, Fletcher AA, Landa K. et al. Multidimensional immunophenotyping of intraductal papillary mucinous neoplasms reveals novel T cell and macrophage signature. Ann Surg Oncol 2022; 29 (12) 7781-7788
    PubMedSearch in Google Scholar
  • 50 Roth S, Zamzow K, Gaida MM. et al. Evolution of the immune landscape during progression of pancreatic intraductal papillary mucinous neoplasms to invasive cancer. EBioMedicine 2020; 54: 102714
    PubMedSearch in Google Scholar
  • 51 Hiraoka N, Onozato K, Kosuge T, Hirohashi S. Prevalence of FOXP3+ regulatory T cells increases during the progression of pancreatic ductal adenocarcinoma and its premalignant lesions. Clin Cancer Res 2006; 12 (18) 5423-5434
    PubMedSearch in Google Scholar
  • 52 Kobayashi N, Kubota K, Kato S. et al. FOXP3+ regulatory T cells and tumoral indoleamine 2,3-dioxygenase expression predicts the carcinogenesis of intraductal papillary mucinous neoplasms of the pancreas. Pancreatology 2010; 10 (05) 631-640
    PubMedSearch in Google Scholar
  • 53 Li J, Wei T, Ma K. et al. Single-cell RNA sequencing highlights epithelial and microenvironmental heterogeneity in malignant progression of pancreatic ductal adenocarcinoma. Cancer Lett 2024; 584: 216607
    PubMedSearch in Google Scholar
  • 54 Ma P, Beatty PL, McKolanis J, Brand R, Schoen RE, Finn OJ. Circulating myeloid derived suppressor cells (MDSC) that accumulate in premalignancy share phenotypic and functional characteristics with MDSC in cancer. Front Immunol 2019; 10: 1401
    PubMedSearch in Google Scholar
  • 55 Cescon DW, Bratman SV, Chan SM, Siu LL. Circulating tumor DNA and liquid biopsy in oncology. Nat Cancer 2020; 1 (03) 276-290
    PubMedSearch in Google Scholar
  • 56 Krebs MG, Malapelle U, André F. et al. Practical considerations for the use of circulating tumor DNA in the treatment of patients with cancer: a narrative review. JAMA Oncol 2022; 8 (12) 1830-1839
    PubMedSearch in Google Scholar
  • 57 Kristensen LS, Jakobsen T, Hager H, Kjems J. The emerging roles of circRNAs in cancer and oncology. Nat Rev Clin Oncol 2022; 19 (03) 188-206
    CrossrefPubMedSearch in Google Scholar
  • 58 Slack FJ, Chinnaiyan AM. The role of non-coding RNAs in oncology. Cell 2019; 179 (05) 1033-1055
    PubMedSearch in Google Scholar
  • 59 Sharma GG, Okada Y, Von Hoff D, Goel A. Non-coding RNA biomarkers in pancreatic ductal adenocarcinoma. Semin Cancer Biol 2021; 75: 153-168
    PubMedSearch in Google Scholar